Amphilimus- vs. zotarolimus-eluting stents in patients with diabetes mellitus and coronary artery disease: the SUGAR trial

AIM: Patients with diabetes mellitus are at high risk of adverse events after percutaneous revascularization, with no differences in outcomes between most contemporary drug-eluting stents. The Cre8 EVO stent releases a formulation of sirolimus with an amphiphilic carrier from laser-dug wells, and ha...

Descripción completa

Detalles Bibliográficos
Autores principales: Romaguera, Rafael, Salinas, Pablo, Gomez-Lara, Josep, Brugaletta, Salvatore, Gómez-Menchero, Antonio, Romero, Miguel A, García-Blas, Sergio, Ocaranza, Raymundo, Bordes, Pascual, Kockar, Marcelo Jiménez, Salvatella, Neus, Jiménez-Díaz, Victor A, Alameda, Mar, Trillo, Ramiro, Lee, Dae Hyun, Martín, Pedro, López-Benito, María, Freites, Alfonso, Pascual-Tejerina, Virginia, Hernández-Hernández, Felipe, del Blanco, Bruno García, Mohandes, Mohsen, Bosa, Francisco, Pinar, Eduardo, Roura, Gerard, Comin-Colet, Josep, Fernández-Ortiz, Antonio, Macaya, Carlos, Rossello, Xavier, Sabate, Manel, Pocock, Stuart J, Gómez-Hospital, Joan A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Fast Track Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8970998/
https://www.ncbi.nlm.nih.gov/pubmed/34735004
http://dx.doi.org/10.1093/eurheartj/ehab790

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8970998/
https://www.ncbi.nlm.nih.gov/pubmed/34735004
http://dx.doi.org/10.1093/eurheartj/ehab790

Ejemplares similares